

# Stefano Bianchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9087349/publications.pdf>

Version: 2024-02-01

36  
papers

2,702  
citations

331670

21  
h-index

414414

32  
g-index

37  
all docs

37  
docs citations

37  
times ranked

2167  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diurnal Variations of Blood Pressure and Microalbuminuria in Essential Hypertension. American Journal of Hypertension, 1994, 7, 23-29.	2.0	368
2	A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. American Journal of Kidney Diseases, 2003, 41, 565-570.	1.9	295
3	Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. Journal of Hypertension, 1998, 16, 1325-1333.	0.5	285
4	Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International, 2006, 70, 2116-2123.	5.2	282
5	Effect of insulin on renal sodium and uric acid handling in essential hypertension. American Journal of Hypertension, 1996, 9, 746-752.	2.0	248
6	Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications. American Journal of Kidney Diseases, 1999, 34, 973-995.	1.9	160
7	Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study. American Journal of Kidney Diseases, 2005, 46, 45-51.	1.9	128
8	Prevalence of Microalbuminuria in a Large Population of Patients with Mild to Moderate Essential Hypertension. Nephron, 1992, 61, 94-97.	1.8	126
9	Clustering of cardiovascular risk factors in salt-sensitive patients with essential hypertension: Role of insulin. American Journal of Hypertension, 1996, 9, 24-32.	2.0	87
10	Salt Intake and Plasma Atrial Natriuretic Peptide and Nitric Oxide in Hypertension. Hypertension, 1996, 28, 335-340.	2.7	80
11	Insulin Resistance in Microalbuminuric Hypertension. Hypertension, 1995, 26, 789-795.	2.7	72
12	Microalbuminuria in patients with essential hypertension: Effects of several antihypertensive drugs. American Journal of Medicine, 1992, 93, 525-528.	1.5	71
13	Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. Journal of Nephrology, 2019, 32, 499-516.	2.0	63
14	Long-Term Effects of Enalapril and Nifedipine on Urinary Albumin Excretion in Patients with Chronic Renal Insufficiency: A 1-Year Follow-Up. American Journal of Nephrology, 1991, 11, 131-137.	3.1	47
15	Microalbuminuria in Patients With Essential Hypertension. American Journal of Hypertension, 1991, 4, 291-296.	2.0	46
16	A Vitamin E-Coated Polysulfone Membrane Reduces Serum Levels of Inflammatory Markers and Resistance to Erythropoietin-Stimulating Agents in Hemodialysis Patients: Results of a Randomized Cross-Over Multicenter Trial. Blood Purification, 2011, 32, 7-14.	1.8	46
17	Long-Term Effects of a Converting Enzyme Inhibitor and a Calcium Channel Blocker on Urinary Albumin Excretion in Patients With Essential Hypertension. American Journal of Hypertension, 1993, 6, 108-113.	2.0	36
18	Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice. Journal of Nephrology, 2018, 31, 653-664.	2.0	35

#	ARTICLE	IF	CITATIONS
19	Association between hyperlipidemia and microalbuminuria in essential hypertension. <i>Kidney International</i> , 1999, 56, S10-S13.	5.2	32
20	Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension?. <i>Current Opinion in Nephrology and Hypertension</i> , 2000, 9, 143-147.	2.0	30
21	Intensive Versus Conventional Therapy to Slow the Progression of Idiopathic Glomerular Diseases. <i>American Journal of Kidney Diseases</i> , 2010, 55, 671-681.	1.9	29
22	A Delphi consensus panel on nutritional therapy in chronic kidney disease. <i>Journal of Nephrology</i> , 2016, 29, 593-602.	2.0	20
23	Silent ischemia is more prevalent among hypertensive patients with microalbuminuria and salt sensitivity. <i>Journal of Human Hypertension</i> , 2003, 17, 13-20.	2.2	17
24	Divert to ULTRA: Differences in Infused Volumes and Clearance in Two On-Line Hemodiafiltration Treatments. <i>International Journal of Artificial Organs</i> , 2012, 35, 435-443.	1.4	15
25	The renal effects of mineralocorticoid receptor antagonists. <i>International Journal of Cardiology</i> , 2015, 200, 20-24.	1.7	14
26	Metabolic Risk Factors and Markers of Cardiovascular and Renal Damage in Overweight Subjects. <i>American Journal of Hypertension</i> , 2006, 19, 426-431.	2.0	12
27	Relationship between hypertension, diabetes and proteinuria in rural and urban households in Yemen. <i>Journal of Human Hypertension</i> , 2013, 27, 572-579.	2.2	12
28	Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, iii51-iii61.	0.7	11
29	Increased cardiovascular events in hypertensive patients with insulin resistance: A 13-year follow-up. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 314-319.	2.6	9
30	Do HMG-CoA reductase inhibitors improve kidney function? The saga continues. <i>Journal of Nephrology</i> , 2011, 24, 550-553.	2.0	9
31	Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. <i>Journal of Nephrology</i> , 2020, 33, 417-430.	2.0	8
32	Statins and Lipid- Lowering Strategies in Cardiorenal Patients. <i>Contributions To Nephrology</i> , 2011, 171, 143-150.	1.1	7
33	Predicting hyperkalemia in patients with acute kidney injury: time for a change of weaponry. <i>Internal and Emergency Medicine</i> , 2020, 15, 371-372.	2.0	1
34	Microalbuminuria in Patients with Essential Hypertension. <i>Cardiovascular and Renal Implications</i> . , 1998, , 569-584.		1
35	Microalbuminuria in Essential Hypertension. <i>Significance for the Cardiovascular and Renal Systems</i> . , 2000, , 575-586.		0
36	The CKD Patient with Dyslipidemia. , 2014, , 93-110.		0